GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Chimerix Inc (NAS:CMRX) » Definitions » FCF Yield %

Chimerix (Chimerix) FCF Yield % : -74.08 (As of May. 11, 2024)


View and export this data going back to 2013. Start your Free Trial

What is Chimerix FCF Yield %?

FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

As of today, Chimerix's Trailing 12-Month Free Cash Flow is $-64.44 Mil, and Market Cap is $86.99 Mil. Therefore, Chimerix's FCF Yield % for today is -74.08%.

The historical rank and industry rank for Chimerix's FCF Yield % or its related term are showing as below:

CMRX' s FCF Yield % Range Over the Past 10 Years
Min: -104.71   Med: -24.26   Max: -0.54
Current: -74.08


During the past 13 years, the highest FCF Yield % of Chimerix was -0.54%. The lowest was -104.71%. And the median was -24.26%.

CMRX's FCF Yield % is ranked worse than
80.98% of 1556 companies
in the Biotechnology industry
Industry Median: -14.17 vs CMRX: -74.08

Chimerix's FCF Margin % for the quarter that ended in Mar. 2024 was 0.00%.


Chimerix FCF Yield % Historical Data

The historical data trend for Chimerix's FCF Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Chimerix FCF Yield % Chart

Chimerix Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
FCF Yield %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -60.26 -11.90 -17.92 -28.66 -80.82

Chimerix Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
FCF Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -79.87 -53.57 -84.15 -68.17 -74.22

Competitive Comparison of Chimerix's FCF Yield %

For the Biotechnology subindustry, Chimerix's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Chimerix's FCF Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Chimerix's FCF Yield % distribution charts can be found below:

* The bar in red indicates where Chimerix's FCF Yield % falls into.



Chimerix FCF Yield % Calculation

FCF Yield % is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

Chimerix's FCF Yield % for the fiscal year that ended in Dec. 2023 is calculated as

FCF Yield %=Free Cash Flow / Market Cap
=-69.177 / 85.59445125
=-80.82%

Chimerix's annualized FCF Yield % for the quarter that ended in Mar. 2024 is calculated as

FCF Yield %=Free Cash Flow * Annualized Factor / Market Cap
=-17.545 * 4 / 94.563024
=-74.22%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Chimerix FCF Yield % Explanation

Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.


Chimerix FCF Yield % Related Terms

Thank you for viewing the detailed overview of Chimerix's FCF Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.


Chimerix (Chimerix) Business Description

Traded in Other Exchanges
Address
2505 Meridian Parkway, Suite 100, Durham, NC, USA, 27713
Chimerix Inc. is a biopharmaceutical company based in the United States that engages in the research, development, and commercialization of medicines. Its portfolio includes treatment for acute myeloid leukemia (or AML) and antiviral treatment for smallpox. The company generates revenue through license agreements and a federal contract with the U.S. Biomedical Advanced Research and Development Authority (BARDA) for research and advanced development of drugs to treat various human diseases. The company operates only in one business segment namely pharmaceuticals.
Executives
Fred A Middleton director 400 SOUTH EL CAMINO REAL STE 1200, SAN MATEO CA 94402-1708
David Jakeman officer: Principal Accounting Officer C/O CHIMERIX, INC.,, 2505 MERIDIAN PARKWAY, SUITE 100, DURHAM NC 27713
Michael A. Sherman director, officer: Chief Executive Officer 3000 KENT AVE STE A1-100, WEST LAFAYETTE IN 47906
Martha J Demski director 7770 REGENTS ROAD SUITE 113-505, SAN DIEGO CA 92122
Robert J. Meyer director 2505 MERIDIAN PARKWAY, C/O CHIMERIX, INC, SUITE 100, DURHAM NC 27713
Michael T. Andriole officer: Chief Business Officer C/O ENDOCYTE, INC., 3000 KENT AVENUE, SUITE A1-100, WEST LAFAYETTE IN 47906
Cantex Pharmaceuticals, Inc. 10 percent owner 1792 BELL TOWER LANE, SUITE 222, WESTON FL 33326
Victoria Vakiener director C/O EPIZYME, INC., 400 TECHNOLOGY SQUARE, CAMBRIDGE MA 02139
Allen S. Melemed officer: Chief Medical Officer C/O CHIMERIX, INC., 2505 MERIDIAN PARKWAY, SUITE 100, DURHAM NC 27713
Pratik S Multani director C/O FATE THERAPEUTICS, INC., 3535 GENERAL ATOMICS COURT, SUITE 200, SAN DIEGO CA 92121
William Garrett Nichols officer: Chief Medical Officer C/O CANDEL THERAPEUTICS, INC., 117 KENDRICK ST SUITE 450, NEEDHAM MA 02494
Michael Albert Alrutz officer: Principal Executive Officer 2530 MERIDIAN PARKWAY, 2ND FLOOR, DURHAM NC 27713
M Michelle Berrey officer: Chief Medical Officer 303A COLLEGE ROAD EAST, PRINCETON NJ 08450
Ernest Mario director 20 FAIRMOUNT AVENUE, P.O. BOX 445, CHATHAM NJ 07928
Ed Greissing director 2505 MERIDIAN PARKWAY, C/O CHIMERIX, INC, SUITE 100, DURHAM NC 27713